Clinical trial
MK0429 Study in Prostate Cancer Patients With Metastatic Bone Disease (0429-011)
NCT00302471 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00302471 |
|---|---|
| Title | MK0429 Study in Prostate Cancer Patients With Metastatic Bone Disease (0429-011) |
| Official title | A Phase I, Randomized, Multicenter, Double-Blind Study of MK0429 in the Treatment of Men With Hormone Refractory Prostate Cancer and Metastatic Bone Disease |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Prostatic Neoplasms |
| Intervention type | Drug |
| Interventions | Comparator: MK0429 |
| Enrollment | 29 |
| Start date | Mar 1, 2006 |
| Primary completion | Oct 1, 2007 |
| Completion | Oct 1, 2007 |
| First posted | Mar 14, 2006 |
| Last update posted | Apr 27, 2015 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: